Microbiological and immunological strategies for treatment of inflammatory bowel disease.
Chronic inflammatory bowel diseases such as Crohn's disease or ulcerative colitis, affect around 1 in every 1000 individuals in western countries. They probably result from an inappropriate reaction towards the commensal microflora and are currently treated with anti-inflammatory drugs or surgery. Novel strategies aim at blocking lymphocyte recruitment and activation, improved targeting of therapeutics and modification of gut microflora.
Steidler
L
L
Department of Molecular Biology, Flanders Interuniversity Institute for Biotechnology and Ghent University, KL. Ledeganckstraat 35, B-9000, Gent, Belgium. Lothar.Steidler@dmb001.rug.ac.be
D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D007167:Immunotherapy; D015212:Inflammatory Bowel Diseases / Q000276:immunology* / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D007778:Lactobacillus / Q000502:physiology; D008213:Lymphocyte Activation; D019936:Probiotics / Q000627:therapeutic use